LHF-535 is utilized in the research and development of antiviral drugs, particularly targeting the Hepatitis B Virus (HBV), a DNA virus that causes chronic liver inflammation and can lead to cirrhosis or liver cancer. This compound acts by inhibiting the assembly of viral particles within liver cells, thereby reducing viral spread throughout the body. Additionally, LHF-535 is in clinical trial stages to evaluate its efficacy and safety for treating patients with chronic HBV infection. Preliminary research demonstrates its potential to reduce viral load and restore liver function.